S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Laser breakthrough could send stock soaring 2,467% (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Laser breakthrough could send stock soaring 2,467% (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Laser breakthrough could send stock soaring 2,467% (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Laser breakthrough could send stock soaring 2,467% (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Laser breakthrough could send stock soaring 2,467% (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Laser breakthrough could send stock soaring 2,467% (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Laser breakthrough could send stock soaring 2,467% (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Laser breakthrough could send stock soaring 2,467% (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Laser breakthrough could send stock soaring 2,467% (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Laser breakthrough could send stock soaring 2,467% (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Laser breakthrough could send stock soaring 2,467% (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Laser breakthrough could send stock soaring 2,467% (Ad)
Leading Egyptian opposition politician targeted with spyware, researchers find
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
NASDAQ:IOBT

IO Biotech (IOBT) Stock Forecast, Price & News

$1.47
+0.06 (+4.26%)
(As of 09/22/2023 ET)
Compare
Today's Range
$1.39
$1.48
50-Day Range
$1.39
$2.03
52-Week Range
$1.35
$3.52
Volume
34,766 shs
Average Volume
187,440 shs
Market Capitalization
$96.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.50

IO Biotech MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
410.2% Upside
$7.50 Price Target
Short Interest
Healthy
3.59% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$6 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.21) to ($1.44) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

559th out of 965 stocks

Pharmaceutical Preparations Industry

258th out of 456 stocks


IOBT stock logo

About IO Biotech (NASDAQ:IOBT) Stock

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

IOBT Price History

IOBT Stock News Headlines

IO Biotech's (IOBT) Buy Rating Reiterated at HC Wainwright
H.C. Wainwright Remains a Buy on IO Biotech (IOBT)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
10 Best New Penny Stocks to Buy Now
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
IO Biotech (IOBT) Gets a Buy from H.C. Wainwright
IO Biotech Announces 2023 Second Quarter Results
TD Cowen Reaffirms Their Buy Rating on IO Biotech (IOBT)
Why Are IO Biotech Shares Trading Lower Today
Jefferies Reaffirms Their Buy Rating on IO Biotech (IOBT)
H.C. Wainwright Reaffirms Their Buy Rating on IO Biotech (IOBT)
IO Biotech GAAP EPS of -$0.59 beats by $0.09
IO Biotech Announces 2023 First-Quarter Results
See More Headlines
Receive IOBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IO Biotech and its competitors with MarketBeat's FREE daily newsletter.

IOBT Company Calendar

Last Earnings
8/11/2023
Today
9/24/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IOBT
Fax
N/A
Employees
57
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.50
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+410.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-71,460,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.82 per share

Miscellaneous

Free Float
63,575,000
Market Cap
$96.84 million
Optionable
Not Optionable
Beta
-0.64
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Mai-Britt Zocca Ph.D. (Age 55)
    Founder, Pres, CEO, Principal Financial Officer & Director
    Comp: $733.88k
  • Ms. Amy B. Sullivan M.B.A. (Age 53)
    Chief Financial Officer
    Comp: $391.24k
  • Prof. Inge Marie Svane M.D.
    Ph.D., Founder & Clinical Advisor
  • Prof. Mads Hald Andersen M.D.
    Ph.D., Founder & Scientific Advisor
  • Anders Ljungqvist
    Founder
  • Prof. Per Thor Straten
    Founder
  • Mr. Brian Burkavage (Age 39)
    Chief Accounting Officer
  • Mr. Eric Faulkner M.B.A.
    Chief Technical Officer
  • Mr. Devin Whittemore Smith (Age 55)
    Sec., Gen. Counsel & Chief Compliance Officer
  • Mr. Daniel G. Mannix Ph.D.
    Sr. VP of Regulatory Affairs













IOBT Stock - Frequently Asked Questions

Should I buy or sell IO Biotech stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IO Biotech in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IOBT shares.
View IOBT analyst ratings
or view top-rated stocks.

What is IO Biotech's stock price forecast for 2023?

2 Wall Street research analysts have issued 1 year price targets for IO Biotech's shares. Their IOBT share price forecasts range from $7.00 to $8.00. On average, they predict the company's share price to reach $7.50 in the next twelve months. This suggests a possible upside of 410.2% from the stock's current price.
View analysts price targets for IOBT
or view top-rated stocks among Wall Street analysts.

How have IOBT shares performed in 2023?

IO Biotech's stock was trading at $2.30 at the beginning of the year. Since then, IOBT stock has decreased by 36.1% and is now trading at $1.47.
View the best growth stocks for 2023 here
.

Are investors shorting IO Biotech?

IO Biotech saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 631,700 shares, an increase of 15.5% from the August 15th total of 546,900 shares. Based on an average daily trading volume, of 212,300 shares, the short-interest ratio is currently 3.0 days. Approximately 3.6% of the company's shares are short sold.
View IO Biotech's Short Interest
.

When is IO Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our IOBT earnings forecast
.

How were IO Biotech's earnings last quarter?

IO Biotech, Inc. (NASDAQ:IOBT) posted its quarterly earnings results on Friday, August, 11th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.66) by $0.08.

When did IO Biotech IPO?

(IOBT) raised $111 million in an IPO on Friday, November 5th 2021. The company issued 7,150,000 shares at a price of $14.00-$17.00 per share.

What is IO Biotech's stock symbol?

IO Biotech trades on the NASDAQ under the ticker symbol "IOBT."

Who are IO Biotech's major shareholders?

IO Biotech's stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.24%), Summit Trail Advisors LLC (0.15%), Citadel Advisors LLC (0.13%) and Two Sigma Securities LLC (0.05%). Insiders that own company stock include Amy Sullivan and Vivo Capital Ix, Llc.
View institutional ownership trends
.

How do I buy shares of IO Biotech?

Shares of IOBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IO Biotech's stock price today?

One share of IOBT stock can currently be purchased for approximately $1.47.

How much money does IO Biotech make?

IO Biotech (NASDAQ:IOBT) has a market capitalization of $96.84 million. The company earns $-71,460,000.00 in net income (profit) each year or ($2.58) on an earnings per share basis.

How can I contact IO Biotech?

The official website for the company is www.iobiotech.com. The company can be reached via phone at 45-7070-2980 or via email at mci@iobiotech.com.

This page (NASDAQ:IOBT) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -